CLINICAL AND PHARMACOLOGICAL PRINCIPLES OF DRUG ADMINISTRATION IN NEONATES AND YOUNG CHILDREN: AN ONTOGENETIC PERSPECTIVE

Authors

  • Khasanov Zakir Khushbokovich Shurchi Abu Ali ibn Sina Public Health Technical College Senior Lecturer, Department of Pharmaceutical Sciences Author

Keywords:

Neonatal pharmacology; Pediatric pharmacotherapy; Pharmacokinetic ontogeny; Individualized dosing; Therapeutic drug monitoring (TDM); PBPK modeling; Excipient toxicity; Medication safety.

Abstract

Background: Pharmacotherapy in neonates and early childhood differs fundamentally from adult clinical protocols due to dynamic physiological and biochemical ontogeny. Functional immaturity of hepatic enzyme systems, renal clearance, and blood-brain barrier permeability profoundly alters drug disposition, increasing the risk of subtherapeutic exposure or severe iatrogenic toxicity when adult doses are linearly extrapolated.

Objective: This narrative review synthesizes contemporary clinical-pharmacological evidence regarding: (1) age-dependent alterations in drug absorption, distribution, metabolism, and excretion (ADME ontogeny); and (2) individualized dosing strategies, excipient safety, rational antimicrobial stewardship, and model-informed precision dosing (TDM and PBPK) in pediatric populations.

Methods: A structured narrative review was conducted analyzing peer-reviewed clinical pharmacology studies, pharmacometric modeling reviews, and international regulatory guidelines (FDA, ICH E11A, EMA, WHO) retrieved from PubMed/MEDLINE, Scopus, and ScienceDirect covering the period from 2007 to 2026.

Results: Neonatal ontogeny is characterized by near-neutral gastric pH, elevated total body water (75–85%), reduced plasma albumin levels, immature Phase I (CYP3A4, CYP1A2) and Phase II (UGT) hepatic enzymes, and low glomerular filtration rates (25–40% of adult values). Consequently, hydrophilic drugs require higher loading doses per kilogram, whereas renally cleared and glucuronidated medications demand extended dosing intervals. Furthermore, pharmaceutical excipients such as benzyl alcohol and propylene glycol pose life-threatening metabolic risks in neonates.

Conclusion: Safe and effective pediatric pharmacotherapy requires abandoning simple weight-based linear scaling in favor of individualized dosing frameworks anchored in postmenstrual age (PMA), organ maturation, excipient screening, therapeutic drug monitoring (TDM), and physiologically based pharmacokinetic (PBPK) modeling.

References

1.Allegaert K, Yalcin N, Flint RB, Simons SHP. Neonatal Clinical Pharmacology. Children. 2024;11(9):1102. doi:10.3390/children11091102.

2.Shaniv D, Allegaert K. Applied pharmacokinetics to improve pharmacotherapy in neonatal and paediatric intensive care units: focus on correct dose selection. Archives of Disease in Childhood – Education and Practice Edition. 2024;109(5):234–241. doi:10.1136/archdischild-2023-326325.

3.U.S. Food and Drug Administration (FDA). General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products: Guidance for Industry. Silver Spring, MD: FDA; July 2022.

4.International Council for Harmonisation (ICH). ICH Harmonised Guideline E11A: Pediatric Extrapolation. Final Step 4 Version; December 2024.

5.Staub E, Bolisetty S, Allegaert K, Raaijmakers A. Neonatal Kidney Function, Injury and Drug Dosing: A Contemporary Review. Children. 2025;12(3):339. doi:10.3390/children12030339.

6.Rodríguez-Báez AS, Kreuzberger N, Iannizzi C, et al. Application of Pharmacometric Modelling Towards Precise Dosing in Neonates, Infants and Toddlers: A Scoping Review. Clinical Pharmacokinetics. 2026;65(11):1629–1666. doi:10.1007/s40262-026-01670-0.

7.Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology — drug disposition, action, and therapy in infants and children. New England Journal of Medicine. 2003;349(12):1157–1167.

8.Tibbetts E. Pharmacokinetics in Children. MSD Manual Professional Edition. Updated July 2025.

9.U.S. Food and Drug Administration (FDA). General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products: Guidance for Industry. Silver Spring, MD: FDA; September 2022.

10.World Health Organization (WHO). Promoting Safety of Medicines for Children. Geneva: WHO Press; 2007.

11.European Medicines Agency (EMA). Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate. London: EMA; 2009.

12.Fabiano V, Mameli C, Zuccotti GV. Paediatric pharmacology: remember the excipients. Pharmacological Research. 2011;63(5):362–365.

Downloads

Published

2026-11-14